IQVIA Holdings Inc. (IQV)
USD 142.92
(1.2%)
USD 142.92
(1.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 20.56 Billion USD | 5.09% |
| 2022 | 19.57 Billion USD | 4.96% |
| 2021 | 18.64 Billion USD | 1.99% |
| 2020 | 18.28 Billion USD | 7.63% |
| 2019 | 16.98 Billion USD | 8.93% |
| 2018 | 15.59 Billion USD | 8.42% |
| 2017 | 14.38 Billion USD | 16.49% |
| 2016 | 12.34 Billion USD | 189.72% |
| 2015 | 4.26 Billion USD | 6.29% |
| 2014 | 4 Billion USD | 7.38% |
| 2013 | 3.73 Billion USD | -3.21% |
| 2012 | 3.85 Billion USD | 17.18% |
| 2011 | 3.29 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 20.21 Billion USD | 2.69% |
| 2024 Q2 | 19.68 Billion USD | -2.7% |
| 2024 Q1 | 20.23 Billion USD | -1.65% |
| 2023 Q2 | 20.28 Billion USD | 2.43% |
| 2023 Q3 | 20.17 Billion USD | -0.57% |
| 2023 Q4 | 20.56 Billion USD | 1.97% |
| 2023 FY | 20.56 Billion USD | 5.09% |
| 2023 Q1 | 19.8 Billion USD | 1.2% |
| 2022 Q1 | 19.05 Billion USD | 2.16% |
| 2022 FY | 19.57 Billion USD | 4.96% |
| 2022 Q2 | 19.06 Billion USD | 0.06% |
| 2022 Q4 | 19.57 Billion USD | 3.69% |
| 2022 Q3 | 18.87 Billion USD | -0.97% |
| 2021 Q3 | 18.2 Billion USD | 0.15% |
| 2021 Q2 | 18.17 Billion USD | -0.29% |
| 2021 Q1 | 18.23 Billion USD | -0.3% |
| 2021 FY | 18.64 Billion USD | 1.99% |
| 2021 Q4 | 18.64 Billion USD | 2.43% |
| 2020 Q4 | 18.28 Billion USD | 3.12% |
| 2020 FY | 18.28 Billion USD | 7.63% |
| 2020 Q1 | 17.27 Billion USD | 1.7% |
| 2020 Q2 | 17.33 Billion USD | 0.32% |
| 2020 Q3 | 17.73 Billion USD | 2.3% |
| 2019 Q2 | 16.28 Billion USD | 0.26% |
| 2019 Q3 | 16.49 Billion USD | 1.3% |
| 2019 Q1 | 16.24 Billion USD | 4.16% |
| 2019 FY | 16.98 Billion USD | 8.93% |
| 2019 Q4 | 16.98 Billion USD | 2.97% |
| 2018 Q2 | 15.01 Billion USD | 1.56% |
| 2018 FY | 15.59 Billion USD | 8.42% |
| 2018 Q4 | 15.59 Billion USD | 3.7% |
| 2018 Q3 | 15.03 Billion USD | 0.17% |
| 2018 Q1 | 14.78 Billion USD | 2.77% |
| 2017 Q1 | 13.38 Billion USD | 8.38% |
| 2017 FY | 14.38 Billion USD | 16.49% |
| 2017 Q4 | 14.38 Billion USD | -3.71% |
| 2017 Q3 | 14.93 Billion USD | 6.64% |
| 2017 Q2 | 14 Billion USD | 4.67% |
| 2016 FY | 12.34 Billion USD | 189.72% |
| 2016 Q4 | 12.34 Billion USD | 193.25% |
| 2016 Q3 | 4.21 Billion USD | 0.46% |
| 2016 Q2 | 4.19 Billion USD | 0.06% |
| 2016 Q1 | 4.18 Billion USD | -1.72% |
| 2015 Q3 | 4.21 Billion USD | 4.21% |
| 2015 Q2 | 4.04 Billion USD | 5.05% |
| 2015 Q1 | 3.84 Billion USD | -4.01% |
| 2015 FY | 4.26 Billion USD | 6.29% |
| 2015 Q4 | 4.26 Billion USD | 1.15% |
| 2014 Q2 | 3.6 Billion USD | -0.58% |
| 2014 Q3 | 3.64 Billion USD | 1.19% |
| 2014 Q1 | 3.62 Billion USD | -3.02% |
| 2014 FY | 4 Billion USD | 7.38% |
| 2014 Q4 | 4 Billion USD | 10.07% |
| 2013 Q3 | 3.55 Billion USD | 3.13% |
| 2013 FY | 3.73 Billion USD | -3.21% |
| 2013 Q2 | 3.44 Billion USD | -8.08% |
| 2013 Q1 | 3.74 Billion USD | -2.83% |
| 2013 Q4 | 3.73 Billion USD | 5.07% |
| 2012 FY | 3.85 Billion USD | 17.18% |
| 2012 Q4 | 3.85 Billion USD | 0.0% |
| 2011 FY | 3.29 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Agilent Technologies, Inc. | 4.91 Billion USD | -318.239% |
| Charles River Laboratories International, Inc. | 4.53 Billion USD | -353.461% |
| Quest Diagnostics Incorporated | 7.6 Billion USD | -170.502% |
| Danaher Corporation | 30.99 Billion USD | 33.644% |
| Enzo Biochem, Inc. | 29.65 Million USD | -69268.002% |
| Laboratory Corporation of America Holdings | 8.83 Billion USD | -132.823% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -486.765% |
| Qiagen N.V. | 2.3 Billion USD | -791.426% |
| Revvity, Inc. | 5.69 Billion USD | -261.372% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 60.356% |
| Waters Corporation | 3.47 Billion USD | -491.656% |